NMPA Accepts Roche’s Crovalimab Filing for PNH Treatment with Priority Review
The National Medical Products Administration (NMPA) has officially accepted for review the market filing submitted...
Company
Kintor Pharma Completes GT20029 Phase I Study for Hair Loss and Acne
China-based Kintor Pharmaceutical Ltd (HKG: 9939) announced the completion of dosing all 92 subjects in...
NHSA Cracks Down on Price Gouging in Basic Medical Insurance Scheme
The National Healthcare Security Administration (NHSA) has announced the results of a special investigation, revealing...
FibroGen’s Roxadustat Sales in China Rise Despite Price Cut
US firm FibroGen Inc. (NASDAQ: FGEN), which operates subsidiaries in Beijing and Shanghai, released its...
Inmagene and HutchMed Dose First Subject in IMG-004 Phase I Study
China-based Inmagene Biopharmaceuticals and Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) announced that the...
Zai Lab’s Q2 2022 Financials Show Revenue Growth and R&D Cost Cut
China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) released its Q2 2022 financial report,...
BeiGene’s Tislelizumab Meets Primary Endpoint in Global HCC Study
BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) announced that the global Phase III RATIONALE 301...
Innovent Biologics’ IBI-112 Achieves Primary Endpoints in Psoriasis Phase II Trial
China-based Innovent Biologics Inc. (HKG: 1801) announced that its interleukin-23 subunit p19 (IL-23p19) monoclonal antibody...
Sciwind’s XW003 Shows Positive Weight Loss Results in Phase Ic/IIa Study
Hangzhou-based Sciwind announced positive interim topline results from a 26-week Phase Ic/IIa clinical study of...
Hansoh Pharma Licenses TiumBio’s TU2670 for Endometriosis Treatment in Greater China
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced a licensing agreement with South Korea’s...
Gan & Lee Pharmaceuticals’ GZR4 Wins FDA Approval for Diabetes Treatment
China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that it has received clinical trial approval...
HeNan Genuine Biotech Sets Azvudine Price at RMB300 per Bottle for COVID-19 Therapy
China-based HeNan Genuine Biotech Co., Ltd has set the price of its COVID-19 therapy azvudine...
Sinotherapeutics Inc. to Raise RMB600m via STAR Board IPO for Generic Drug Expansion
Sinotherapeutics Inc., a Shanghai-based generic drug developer, is set to make an initial public offering...
NMPA Approves BioFire Diagnostics’ Encephalitis/Meningitis Detection Kit
The National Medical Products Administration (NMPA) website indicates that BioFire Diagnostics LLC’s encephalitis/meningitis multiple pathogen...
BioDuro-Sundia and X-Chem Form Long-Term Partnership for Drug Discovery
Two China-based companies, the Contract Research, Development, and Manufacturing Organization (CRDMO) BioDuro-Sundia and X-Chem, have...
Dizal Pharma’s Sunvozertinib Shows Promise in NSCLC with EGFR Exon 20 Insertion
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has unveiled the latest positive data for its...
Hywin Holdings to Acquire Life Infinity for Health Management Expansion
China-based wealth management firm Hywin Holdings is set to move into the health management business...
HutchMed’s FRESCO-2 Study for Elunate in Colorectal Cancer Meets Primary Endpoint
China-based Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) announced that the pivotal global Phase...
Frontier Biotech Partners with Kindstar to Boost Anti-Infection Testing, Especially for HIV
China-based Frontier Biotechnologies Inc. (SHA: 688221) has entered into a partnership with compatriot firm Kindstar...
Innovent Biologics Doses First Subject in IBI324 Phase I Study for DME
China-based biotech Innovent Biologics Inc. (HKG: 1801) announced that the first subject has been dosed...